Outcome-Driven Personalized Treatment Design for Managing Diabetes

The authors developed a model that incorporates two mathematical innovations for designing a personalized treatment plan tailored specifically to a diabetes patient’s unique dose-effect characteris...

[1]  A. Hill.  The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. , 1913, The Biochemical journal.

[2]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[3]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[4]  C. Peterson,et al.  Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. , 1989, American journal of obstetrics and gynecology.

[5]  L. Jovanovič,et al.  Gestational diabetes mellitus. , 2001, JAMA.

[6]  Pharmacokinetic‐pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability , 2001, The Journal of pharmacy and pharmacology.

[7]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[8]  N. Holford,et al.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. , 2003, British journal of clinical pharmacology.

[9]  Y. Hamamoto,et al.  Guidelines for computer modeling of diabetes and its complications. , 2004, Diabetes care.

[10]  W. Winter,et al.  A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  V. Petkova,et al.  A pharmacoeconomical model for choice of a treatment for pregnant women with gestational diabetes , 2007, Acta Diabetologica.

[12]  D. Pettitt,et al.  Screening for Gestational Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[13]  William J. Jusko,et al.  Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus , 2008, Clinical pharmacokinetics.

[14]  T. Dall,et al.  Cost of gestational diabetes mellitus in the United States in 2007. , 2009, Population health management.

[15]  S. Jacqueminet,et al.  Therapeutic management of gestational diabetes. , 2010, Diabetes & metabolism.

[16]  Ping Zhang,et al.  Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. , 2013, American journal of preventive medicine.

[17]  J. Cullinan,et al.  Modeling the Independent Effects of Gestational Diabetes Mellitus on Maternity Care and Costs , 2013, Diabetes Care.

[18]  J. Ulbrecht,et al.  Personalized State-space Modeling of Glucose Dynamics for Type 1 Diabetes Using Continuously Monitored Glucose, Insulin Dose, and Meal Intake , 2014, Journal of diabetes science and technology.

[19]  L. Geiss,et al.  Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. , 2015, JAMA.

[20]  Ping Zhang,et al.  Economic Costs of Diabetes in the U.S. in 2017 , 2018, Diabetes Care.